State-level Status for Evidence-Based Psychedelic Research for Mental Health and Trauma Care

Take action and stay informed by becoming an AACPN member today

Arizona

Arizona has emerged as an important state in the broader “Right-to-Try 2.0” movement, which allows certain seriously ill patients expanded access to investigational therapies. While not specific solely to psychedelics, these frameworks could influence future access pathways involving psychedelic-assisted treatments and individualized mental health therapies.

Arkansas

Arkansas enacted a Right-to-Try 2.0 framework in 2025, contributing to broader national efforts to expand access to investigational therapies and emerging treatment models for serious illnesses.

California

California lawmakers continue advancing psychedelic research-related legislation and regulatory discussions. In 2026, Assembly Bill 2489 advanced discussions surrounding psychedelic research compounds and synthetic psilocybin analogs designed for therapeutic use.

Colorado

Colorado remains one of the most advanced psychedelic policy states in the country. The state’s Natural Medicine program has created regulated pathways for supervised psilocybin services and related healing center models. Colorado lawmakers are also actively preparing state systems for future federal approvals involving psychedelic-assisted therapies.

Connecticut

Connecticut has become a national leader in veteran-focused psychedelic research. The state expanded and extended its psychedelic-assisted therapy pilot program involving PTSD, depression, and trauma-related conditions in partnership with Yale School of Medicine. Originally focused on veterans, retired first responders, and healthcare workers, the program is now expanding eligibility to broader patient populations.

Georgia

Georgia adopted Right-to-Try 2.0 legislation in 2025, creating additional frameworks that may eventually support investigational psychedelic-assisted treatment access pathways.

Indiana

Indiana enacted Right-to-Try 2.0 legislation in 2025 amid growing national interest in investigational therapies for severe mental health and neurological conditions.

Iowa

Iowa lawmakers have considered psilocybin regulation and broader psychedelic policy proposals as interest in therapeutic research expands nationally.

Kansas

Kansas enacted Right-to-Try 2.0 legislation in 2025, joining a growing group of states pursuing expanded investigational treatment frameworks.

Louisiana

Louisiana lawmakers have adopted legislation supporting psychedelic drug research involving mental illness, addiction, and emerging behavioral health treatments. The state has also adopted broader investigational treatment access legislation in recent years.

Maryland

Maryland adopted Right-to-Try 2.0 legislation in 2024, contributing to national momentum surrounding investigational treatment access frameworks.

Massachusetts

Massachusetts lawmakers continue evaluating psychedelic-assisted therapy proposals, including research-focused legislation and discussions involving ibogaine-related treatment studies and regulated therapeutic access models.

Minnesota

Minnesota lawmakers recently advanced legislation creating a supervised psilocybin pilot program for patients with qualifying medical conditions including PTSD, chronic pain, and substance use disorder. The proposal received bipartisan support and would establish a carefully regulated therapeutic framework.

Mississippi

Mississippi enacted Right-to-Try 2.0 legislation in 2024 as part of broader national investigational treatment reforms.

Missouri

Missouri lawmakers introduced legislation supporting psilocybin-assisted treatment access for veterans suffering from PTSD and related trauma conditions.

Nevada

Nevada enacted Right-to-Try 2.0 legislation in 2023, supporting broader investigational therapy access pathways.

New Hampshire

New Hampshire adopted Right-to-Try 2.0 legislation in 2025 amid growing national momentum surrounding experimental treatment access policies.

New Jersey

New Jersey enacted a $6 million Psilocybin Behavioral Health Access and Therapy Pilot Program focused on hospital-based and clinically supervised therapeutic research models. The program represents one of the more institutionally focused state approaches to psychedelic-assisted treatment policy.

New Mexico

New Mexico enacted legislation creating a medical psilocybin program and is currently developing the regulatory and clinical framework necessary for implementation.

New York

New York lawmakers have proposed a major psilocybin-assisted therapy pilot program focused on veterans, first responders, and patients suffering from cluster headaches and trauma-related conditions. The proposal would involve SUNY-affiliated medical research participation and state-supported funding.

North Carolina

North Carolina enacted Right-to-Try 2.0 legislation in 2024, expanding investigational therapy access pathways.

Oregon

Oregon remains the first state in the nation to fully implement a regulated psilocybin services program. The state’s supervised access model continues serving as one of the primary national reference points for psychedelic-assisted therapy regulation and oversight.

South Dakota

South Dakota passed psilocybin therapy legislation in 2026, further expanding the number of states evaluating regulated psychedelic-assisted treatment frameworks.

Texas

Texas has emerged as one of the most aggressive states supporting psychedelic research, particularly involving ibogaine therapy for addiction, neurological trauma, PTSD, and traumatic brain injury. In 2025, Governor Greg Abbott signed legislation authorizing major state-supported ibogaine research funding initiatives.

Utah

Utah enacted legislation supporting state-funded psychedelic-assisted therapy research focused on veterans with treatment-resistant PTSD and related trauma conditions.

Vermont

Vermont established a Psychedelic Therapy Advisory Working Group and continues evaluating future therapeutic and regulatory frameworks involving psychedelic-assisted therapies and decriminalization proposals.

Washington

Washington State enacted legislation establishing a psilocybin medical use framework and continues evaluating broader supervised therapeutic access models.

Latest on the issue

AACPN Launches Psychedelic Research Initiative to Advance Veteran Mental Health Innovation

The American Alternative Care Policy Network (AACPN) this week launched its Psychedelic Research Initiative to support continued scientific research into emerging therapies that may help address some of America's most difficult mental health challenges. At the center of this effort are veterans. For many veterans, the invisible wounds of service can persist long after they return home. Post-traumatic stress, depression, anxiety, traumatic brain injury, substance-use disorders

AACPN Applauds Connecticut Enactment of Public Act 26-108 Expanding Psychedelic-Assisted Therapy Research

AACPN applauds Connecticut’s enactment of Public Act 26-108, expanding the state’s psychedelic-assisted therapy pilot program and supporting continued clinical research involving MDMA and psilocybin therapies for veterans, first responders, trauma survivors, and individuals living with treatment-resistant mental health conditions.

Veteran participating in a clinical mental health research session as the U.S. Department of Veterans Affairs launches a study evaluating MDMA-assisted therapy for PTSD and alcohol use disorder among veterans and trauma survivors.

AACPN Statement on VA MDMA-Assisted Therapy Trial

AACPN welcomes the U.S. Department of Veterans Affairs’ launch of a clinical trial evaluating MDMA-assisted therapy for veterans living with PTSD and alcohol use disorder. The organization says rigorous scientific research is essential to understanding whether emerging therapies can safely and effectively support veterans and other trauma survivors facing complex behavioral health challenges.